Member Info for BIGBONE

With th

Allegedly the short position is less than 0.2%

:)

The US "Shadow" Trading (OTCQX/OTC)

​When people talk about Hemogenyx being "dual listed" in the US, they are usually referring to its presence on the OTC Markets (ticker: HGELF or HOPHF).

​It’s not a "Listing" in the traditional sense: Unlike the NASDAQ or NYSE, the OTC market is a decentralized dealer network. Hemogenyx doesn't have to meet the same grueling requirements as a US-listed company because it uses its LSE compliance to qualify for trading in the US.

​Why it might look "gone": Sometimes, OTC tickers can become "Grey Market" or "Expert Market" only, meaning they are still technically there, but your specific broker might not allow you to buy or sell them. This can give the illusion that the company isn't on an exchange at all..

Expert only then :)

Lostapound.

Yes, Hemogenyx Pharmaceuticals plc is dual-listed.

Primary Listing: London Stock Exchange (LSE) under the ticker HEMO.

Secondary Listing: OTC (Pink Sheets) in the US under the ticker HOPHF.

Key Details as of early 2026:

Recent Activity: The company underwent a 1-for-400 stock split for its US-traded shares (HOPHF) in December 2024.

Business Focus: Clinical-stage biotech firm developing therapies for blood cancers (e.g., HEMO-CAR-T).

Market Position: As of Jan 2026, the stock has shown high volatility and recent growth.

Have we just dual listed .

PINK:HOPHF

Accumulating *

Short term if the share price can get past the blocking trades at £7 its a run up to £10-11 a share . Being held in place speculation is someone still accusing at these prices but not for much longer not much free float left.

Like many here have a substantial holding after 4 years of accumulating LTH here.

Not many shares in free float . Smart money already positioning.

Aquis DGQ.PL went up 35 % + after gave the tip.

Not much free float . Seems to being bought up steadily. Hold for gold ,

Pumpky ,

how did you get on with the gold play .

Hemogenyx Pharmaceuticals does not currently have a primary active partnership with a Chinese company for its lead CAR-T therapy development. Instead, the company has focused its recent strategic collaborations on US-based and European partners.

​However, there is a significant connection to China regarding their Intellectual Property (IP):

​1. Chinese Intellectual Property & Patents

​In August 2022, the China National Intellectual Property Administration (CNIPA) granted Hemogenyx a patent for its bi-specific antibody (CDX) technology. This patent allows Hemogenyx to protect its inventions in the Chinese market, which they have identified as one of the largest global markets for cancer treatment.

​2. Major Active Partners (Non-Chinese)

​If you are looking for the companies Hemogenyx is currently "working with" for their clinical trials and manufacturing, they are:

​Made Scientific (USA): A New Jersey-based CDMO (Contract Development and Manufacturing Organization) announced in September 2025 as the primary partner for the manufacturing and technology transfer of HG-CT-1.

​**Cellin Technologies (Estonia): A partnership signed in late 2025 to commercialize HG-CT-1 in Europe under the "hospital exemption" pathway.

​Kure.ai (USA): Collaborating on an "ultrafast" CAR-T manufacturing platform.

​Prevail InfoWorks (USA): Providing clinical services and data analytics for their Phase I studies.

​Summary of Connection

​While Hemogenyx holds a license from Cornell University that covers regions including China, and has secured Chinese patents to protect its assets there, they have not yet announced a Chinese-based biotech or pharmaceutical partner to co-develop or distribute their therapies within China.

Looking like going global!

BWTFDIK.

Silence is deafening . So much news to arrive will we get blue sky's.

Pumpky.

Seen as you are sharing.

DGQ.pl Delta gold as always DYOR

Simply Wall St estimated a Fair Value of £80.00, some users alot more suggesting the stock was significantly undervalued (over 90%) based on long-term revenue projections for its CAR-T leukemia therapies. Source of valuation and agree medium term Billion's once phase ll and FDA safety sign off.

USA analysts have £80 min fair value for Hemogenyx at the moment , so suppressed. Once MRD is released along with safety data and FDA will see a propper rerate as some say not long to wait .

Now listed for buying happy days.

Six weeks to accumulate some shares for the ride. Thanks for posting links.

Pixels.

Hope this helps .

In September 2025, Hemogenyx Pharmaceuticals received a high-profile invitation to participate in the DCNY Summit, which took place in Washington, DC (Sept 18) and New York (Sept 22).

​While the company heavily publicized the invitation as a major milestone, there was no subsequent "event-specific" press release detailing a specific deal or breakthrough directly from the summit floor. Instead, the period immediately following the summit saw a flurry of operational and financial activity.

​Summary of What Happened

​The Invitation (Sept 11, 2025): The company announced it was invited to the summit, which is a curated event co-hosted by the Alliance Indus Foundation and international partners like Saudi Vision Invest. CEO Vladislav Sandler noted it was a "unique opportunity" to engage with global investors and policymakers.

​The Presentations: Hemogenyx presented its clinical progress, specifically focusing on the ongoing Phase I trial of HG-CT-1 CAR-T therapy for AML.

​Post-Summit Outcomes:

​Strategic Expansion: Shortly after the summit dates, on October 6, 2025, the company announced it had received clearance to initiate pediatric enrollment for its AML trial.

​Commercial Interest: Around the same time, they signed a Letter of Intent (LOI) with Cellin Technologies (Sept 23) regarding the commercialization and manufacturing of their treatments.

​Financing: Consistent with the summit's reputation for helping firms "secure growth capital," Hemogenyx spent the final quarter of 2025 focused on equity issues and prospectus publications to solidify its cash position for 2026.

If BMS , Kite or Eli lilly and possibly two more which could incorporate Hemogenyx into already existing cart T with Hemogenyx advances in the tech . Then the sp could really move but does depend on safety data being released and phase two and blue sky .Then possibly a major rerate . 2026-2027 . If not bought out !